IL6 and synovial sarcoma: Therefore, one possible avenue of research is the combination of fenofibrate with iguratimod (anti-rheumatic drug inhibiting TNF-α, IL-1, IL-6, BAFF-R, CD38 signaling) or necrosulfonamide (inhibitor of GSDMD-pore formation) to decrease inflammation, reduce deleterious effects of inflammasome activation, and durably improve the epithelial function in SS.